Introduction D
rug absorption from solid dosage forms after oral administration depends on the release of the drug substance from the drug product, the dissolution or solubilization of the drug under physiological conditions, and the permeability across the gastrointestinal tract. Because of the critical nature of the first two of these steps, in vitro dissolution may be relevant to the prediction of in vivo performance. Based on this general consideration, in vitro dissolution tests for immediate release solid oral dosage forms are used: (a) to assess the lot-to-lot quality of a drug product; (b) to assess the stability of the drug product; (c) to ensure continuing product quality and performance after certain changes, such as changes in the formulation, the manufacturing process, the site of manufacture, and the scale-up of the manufacturing process; and (d) to develop new formulations. In formulation development, dissolution testing can aid in the selection of excipients, help optimize the manufacturing process, and enable formulation of the test product to match the release of the reference product [1 and 2] .
Dissolution testing has emerged in the pharmaceutical field as a very important tool to characterize drug product performance. The dissolution test is an analytical technique that has undergone significant equipment modifications and improvements spanning the last decade. Dissolution has become an important and widely utilized test receiving more emphasis worldwide from regulatory authorities during the last 15 years. The significance of a dissolution test is based on the fact that for a drug to be absorbed and available to the systemic circulation, it must previously be dissolved [3] . Therefore, dissolution tests are used not only for quality control of finished products, but also to assess several stages of formulation development, for screening and proper assessment of different formulations [4] . Basically, the dissolution test makes it possible to assess the dissolution properties of the drug itself and thereby to select the most appropriate excipients and to optimize proportions among them to obtaining the desired drug release behavior. Moreover, when an 'in vitro/in vivo' correlation is available, dissolution can be used as a test to reflect the bioavailability of a product in humans and therefore to determine the actual bioequivalence of different products containing the same drug at the same dosage.
During a preformulation study, preliminary testing conditions are commonly elaborated taking into consideration the state of the art for dissolution testing. Different official apparatus are available and, for each, Compendia, e.g., USP, BP, and EP, report detailed specifications in both general chapters [5 and 6] and individual monographs on solid oral dosage forms. Dissolution tests of conventional dosage forms have been successfully implemented, and formal guidelines exist which provide useful recommendations for their evaluation [7] .
In any case, it is important to point out that none of the purposes for which dissolution tests are used can be fulfilled by an in vitro test without sufficient reliability, where this is defined as a system being experimentally sound, yielding precise, accurate and repeatable results [8] . A recent international collaborative study indicated that drug dissolution testing is a highly variable technique [9] . As a consequence, in many cases the impact of formulation or manufacturing changes on drug release properties may not be detected, or, on the contrary, not true differences, but rather differences caused by test variability, could be recorded. Thus, careful control of experimental conditions is necessary in order to suitably reduce test-to-test variability and improve test reproducibility and reliability.
The validation of the dissolution test can be divided into two parts. The first regards equipment validation; equipment has to be calibrated taking into consideration the specifications for geometry and alignment of the dissolution apparatus [10] . The second concerns test validation; it requires the study of the performance parameter precision [5] . The evaluation of precision is very important in order to assess the reliability of the data obtained by the dissolution test. In fact, it is true that a more discriminating dissolution method is preferred, but it is also true that a reliable dissolution test is of utmost importance. A dissolution test with a good precision, for example, makes it possible to efficiently compare different alternative formulation candidates to select the dosage form with the most suitable and reproducible drug release profile. At the time of the dissolution test development, however, in vivo human data is normally not available. Instead, prior to the human clinical studies, dissolution data must usually be generated without the benefit of comparative rankings between formulations or lots, estimated in vivo absorption rates, or any other information that could be used to guide the development of a discriminating dissolution test [11 and12 ].
Clomipramine is a chlorinated analogue of imipramine with both antidepressant and anti-obsessional properties [13] . Clomipramine is an organic base of highly lipophilic nature. Its HCl salt is freely soluble in water. There is no official method for determination of dissolution rate of clomipramine hydrochloride solid oral dosage forms. A review of the literature indicated that there was no reported dissolution method for clomipramine products. Consequently, the in-house development of a precise, validated, and reliable dissolution method for clomipramine solid oral dosage forms was necessary in order to support the product development and quality control efforts. This paper describes the development and validation of the dissolution methodology for clomipramine solid products.
Experimental 2.1. Materials
Clomipramine HCl pharmaceutical grade was kindly donated by Shahr Daru Pharmaceutical Co. (Iran); Hydrochloric acid (Merck, Darmstadt, Germany), was used as received. Clomipramine HCl film coated tablets were obtained from Shahr Daru Pharmaceutical Co. (Iran); labeled to contain 10 mg, 25 mg, and 50 mg Clomipramine HCl. Anafranil ® capsules contained 10 mg 25 mg, and 50 mg clomipramine HCl manufactured by Novartis (Switzerland). Anafranil ® sugar coated tablets labeled to contain 10 mg clomipramine HCl were obtained from Ciba Geigy (England). Doubly distilled water was used throughout the study.
Preparation of standard solutions
Clomipramine stock standard solution was prepared at a concentration of 100 mg/mL in water. The clomipramine stock standard solution was diluted to obtain the known standard concentrations of 5, 10, 15, 20, 25, 30, 40, and 50 mg/mL in either 1 N HCl or pH 7.0 phosphate buffer. The buffer was prepared by mixing 50 mL of 0.2 M potassium dihydrogen orthophosphate with 29.63 mL of 0.2 M sodium hydroxide volumetric solution and diluting to 200 mL with water. UV absorbance of each standard solution was measured spectrophotometrically (UV/Vis spectrophotometer Shimadzu 2100, Tokyo, Japan) at 252 nm with the mean data (n=6) used for the calibration curve. The concentration of dissolved drug in sample solutions was spectrophotometrically monitored.
Dissolution test conditions and analysis procedure
Dissolution studies on three commercially available products (film coated tablets, sugar coated tablets and capsules) of clomipramine HCl were conducted using USP Apparatus 1 and 2 (basket and paddle method, respectively, Erweka DT80, Germany). The dissolution medium was 900 mL of either pH 1 hydrochloric acid aqueous solution, or pH 7.0 phosphate buffer at 37 ± 0.5 o C and stirred at 50 and 75 rpm. The dissolution test was performed on each product using conditions summarized in Table 1 .
In all experiments, 5 ml sample aliquots were withdrawn at 5, 10, 15, 20, 25, 30, 45, and 60 minutes and replaced with an equal volume of the fresh medium to maintain a constant total volume. Samples were assayed by the previously Development and Validation … continued mentioned spectrophotometric method. Cumulative percentages of the drug dissolved from the products were calculated and plotted vs. time.
4 Applied method to compare dissolution profiles
The description of the in vitro dissolution profiles by using model-independent methods includes the calculation of mean dissolution time (MDT) from the dissolution profile, mean residence time (MRT) from the residence profile, or area under the dissolution curve. In vitro dissolution profiles can statistically be compared through these parameters (14 and 15) . In this study, as model-independent approaches, two fit factors that compare the dissolution profiles of a pair of drug products were applied to the dissolution data. These fit factors directly compare the difference between percent drug dissolved per unit time for a test and a reference product. The fit factors are denoted f1 (difference factor), and f2 (similarity factor) and are defined by Equations. (1) and (2) (16) where n is the number of dissolution sample times, and R t and T t are the individual or mean percent dissolved at each time point, t, for the reference and test dissolution profiles, respectively.
Results and Discussion
The dissolution results as the means of percents dissolved versus time for commercially available tablets and capsules of clomipramine HCl are given in Figures 1  through 3 .
Each data point represents a mean of nine measurements for each product. All drug products had percent of amount dissolved not less than 80% of the labeled amount of clomipramine HCl within 30min. The dissolution method and specification are set by considering the solubility, permeability, dissolution, and pharmacokinetics of the drug substance. Three categories of dissolution test specification for immediate release products are described in the guidance provided by the Center for Drug Evaluation and Research at the Food and Drug Administration (7): (a) single point specifications, (b) two-point specifications, and (c) dissolution profile comparison. The dissolution profile comparison seems to be more precise than the point estimate approach to characterize the drug product (18 -20) . The methods for the comparison of in vitro dissolution profiles can be classified into three groups: (a) the methods based on analysis of variance (ANOVA) (14 and 18) , (b) modeldependent methods (2, 14, and 18) , and (c) model-independent methods (2, 13, 14, 15, and 19) . A model-independent method uses the dissolution data in their native form and was used in this study. The f1 (difference factor) is proportional to the average difference between the two profiles, whereas f2 (similarity factor) is inversely proportional to the average squared difference between the two profiles, with emphasis on the larger difference among all the time points. The use of these factors was also recommended for dissolution profile comparison in the FDA's guides for industry (7) and in this study f2 was calculated and used. According to these guides, f2 values greater than 50 (50-100) would indicate sameness or equivalence of the two curves. F2 factors for each clomipramine dosage form (FC Tablets,T ; Capsule, R 1 ; or SC Tablets R 2 ) at each dissolution condition versus other dissolution conditions were calculated from the means of percent dissolved at each time point by using Equation 2 and listed in tables 2 through 4.
The values of factor f2 were calculated for the dissolution up to 30 minutes (the time at which 80% of drug substance is dissolved from any tested drug product). As can be seen in tables 2 through 4, mean of f2 factor for each condition compared to other conditions were calculated and showed Table 4 . The similarity factor, f 2 , between different dissolution conditions for SC tablet These results show that in conditions such as WB50, in which all strengths of capsules are similar, the biggest difference is between different strengths of tablets. Therefore it seems that if we want to use dissolution conditions which have the most discriminating properties for capsules and film coated tablets , we must use HCl 0.1 N as a medium, USP Apparatus 2 (paddle) as dissolution apparatus and stirring speed of 75 rpm and for sugar coated tablets we must use buffer pH 7.0 as a medium, USP Apparatus 2 (paddle) as dissolution apparatus and stirring speed of 50 rpm in which the mean of f2 factors for all strengths of dosage forms are the lowest, indicating a greater difference for dissolution.
Conclusion
Dissolution testing is a very important in vitro test to evaluate drug products. Clomipramine HCl, used in some depressive conditions such as obsessive compulsive disorders, has no reliable dissolution conditions in its monograph in BP or USP. In this study, we concluded that, if we want to use the most discriminating conditions for dissolution testing of clomipramine capsules or film coated tablets, a HCl media, paddles, and stirring speed of 75 rpm should be used, and for sugar coated tablets, buffer pH 7.0 , paddles, and stirring speed of 50 rpm appear to be the best conditions. 
